Patents by Inventor Peter Kotanko
Peter Kotanko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240127962Abstract: A computing system for determining a systematic training strategy for the user is provided. The computing system includes a user device that uses one or more sensors to obtain partial pressure of oxygen (PO2) levels of a user over a period of time. The user device provides previous PO2 levels to a personalized erythropoiesis model generation computing platform. The computing platform obtains individualized user data for the user indicating or more previous hematocrit and/or hemoglobin measurements for the user. The computing platform determines an individualized erythropoiesis model for the user based on the one or more previous hematocrit and/or hemoglobin measurements and the previous PO2 information, and employs the individualized erythropoiesis model to determine predicted hematocrit and/or hemoglobin measurements. The computing platform performs one or more actions based on the one or more predicted hematocrit and/or hemoglobin measurements.Type: ApplicationFiled: October 5, 2022Publication date: April 18, 2024Inventors: Peter Kotanko, Ulrike Kotanko, Sabrina Casper, David Joerg, Gudrun Schappacher-Tilp, Doris Fuertinger
-
Publication number: 20240127961Abstract: A method for determining a next hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) dosage for a first patient using a patient HIF-PHI model is provided. The method includes obtaining population patient data indicating HIF-PHI dosages and hemoglobin measurements for the patients. Then, virtual patient avatars are generated based on the population patient data. Each of the virtual patient avatars indicates a set of personalized model parameters for a HIF-PHI model. A plurality of HIF-PHI models are determined for the virtual patient avatars. Using the HIF-PHI models, one or more HIF-PHI treatment schemes for administering the HIF-PHI dosages is determined. Subsequently, the HIF-PHI treatment schemes along with a hematocrit and/or hemoglobin concentration for a patient are used to determine a next HIF-PHI dosage for the patient, and the next HIF-PHI dosage is administered for the patient.Type: ApplicationFiled: October 5, 2022Publication date: April 18, 2024Inventors: Doris Fuertinger, David Joerg, Gudrun Schappacher-Tilp, Peter Kotanko
-
Patent number: 11951243Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. The dialysis machine may include at least one processor and a memory coupled to the at least one processor, the memory comprising instructions that, when executed by the processor, may cause the at least one processor to access dialysis information for a dialysis process performed by a dialysis machine, the dialysis information indicating a target substance to be displaced from a binding compound by a displacer, and determine an infusion profile for infusing the displacer into a patient during a displacer infusion process of the dialysis process, the infusion profile determined based on the dialysis information and an infusion constraint. Other embodiments are described.Type: GrantFiled: September 13, 2022Date of Patent: April 9, 2024Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Vaibhav Maheshwari, Peter Kotanko
-
Publication number: 20240074680Abstract: The present teachings include analyzing oxygen saturation levels sensed during a hemodialysis treatment for a patient to determine whether the patient has a medical condition based on hypoxemia, apnea, or the like experienced during the treatment. To this end, the present teachings may include the use of a machine-learning algorithm trained to identify a presence of a high-frequency intermittent pattern that would be formed in a plot of the oxygen saturation levels, e.g., to determine a severity of respiratory instability experienced. The present teaching may also or instead include a time-series analysis including at least one of: (i) calculating recurrence-based quantification, such as, but not limited to, recurrence rate, determinism, and laminarity; (ii) calculating the optimal recurrence threshold based on maximum variations of the system's determinism and degree of predictability; and (iii) calculating complexity-based measures such as permutation entropy.Type: ApplicationFiled: October 31, 2023Publication date: March 7, 2024Inventors: Alhaji Cherif, Peter Kotanko, Paulo Paneque Galuzio, Hanjie Zhang
-
Patent number: 11878098Abstract: A method includes: receiving measurements of a blood-related parameter corresponding to a patient undergoing hemodialysis; estimating a value of one or more hemodialysis treatment-related parameters by applying a vascular refill model based on the received measurements of the blood-related parameter, wherein the one or more hemodialysis treatment-related parameters are indicative of an effect of vascular refill on the patient caused by the hemodialysis; determining, based on the one or more estimated values of the one or more hemodialysis treatment-related parameters, a hemodialysis treatment-related operation; and facilitating performance of the treatment-related operation. The vascular refill model is a two-compartment model based on a first compartment corresponding to blood plasma in the patient's body, a second compartment based on interstitial fluid in the patient's body, and a semi-permeable membrane separating the first compartment and the second compartment.Type: GrantFiled: January 8, 2020Date of Patent: January 23, 2024Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Aurelio A. de los Reyes, V, Doris H. Fuertinger, Franz Kappel, Anna Meyring-Wosten, Stephan Thijssen, Peter Kotanko
-
Publication number: 20230414846Abstract: The present teachings generally include parabiotic dialysis systems and techniques. For example, the present disclosure includes parabiotic liver dialysis, e.g., for use in settings with limited resources. To this end, a parabiotic liver dialysis system may include a device having a semipermeable membrane with an average pore size that allows for the passage of albumin therethrough. In such a system, a first extracorporeal circuit may connect the device to the vascular system of a first animal (e.g., a liver patient), and a second extracorporeal circuit may connect the device to the vascular system of a second animal (e.g., a human with normal liver function), where the exchange of albumin therebetween is facilitated through the device. The present disclosure also includes various safety measures for parabiotic dialysis systems and techniques, such as biometric verification systems and techniques.Type: ApplicationFiled: August 8, 2023Publication date: December 28, 2023Inventors: Stefan Weiss, Peter Kotanko, Roland Sander
-
Publication number: 20230405201Abstract: The described technology may include treatment processes to increase the red blood cell (RBC) population of individuals, particularly chronic kidney disease (CKD) patients with renal anemia, by reducing an amount of Piezo1 chemical agonists in the blood of patients. In one embodiment, a method of treating a patient with renal anemia may include increasing RBC lifespan of an RBC population of the patient via reduction of a Piezo1 channel activation duration of at least a portion of the RBC population by reducing an amount of a target uremic compound in the blood of the patient, the target uremic compound having a form that prolongs the Piezo1 channel activation duration, wherein the amount of the target uremic compound may be reduced via selectively removing at least a portion of the target uremic compound from the blood of the patient. Other embodiments are described.Type: ApplicationFiled: November 12, 2021Publication date: December 21, 2023Inventors: Peter Kotanko, Nadja Grobe, Christoph Zaba, David Joerg, Frank Gebauer
-
Publication number: 20230381385Abstract: The described technology may include processes to model acid-base homeostasis in normal patients and under acid-base disorder conditions. In one embodiment, a method may include an acid-base homeostasis analysis process. The method may include, via a processor of a computing device, providing an acid-base model configured to model acid-base homeostasis of a patient, the acid-base model comprising a patient model, a dialyzer model, and an extracorporeal CO2 removal device (ECCO2RD), and determining predicted patient information using the acid-base model. Other embodiments are described.Type: ApplicationFiled: May 24, 2023Publication date: November 30, 2023Inventors: Alhaji Cherif, Paulo Paneque Galuzio, Peter Kotanko, Juergen Klewinghaus, David Thompson
-
Publication number: 20230380762Abstract: Systems and methods for the image-based determination of the fluid status of a patient are described. In one example, an apparatus may include at least one processor and a memory coupled to the at least one processor. The memory may include instructions that, when executed by the at least one processor, may cause the at least one processor to receive an image that may include at least one image of a portion of a patient, determine fluid status information for the patient by processing the image via a trained computational model, the trained computational model trained based on at least one training image of the patient and a corresponding physical measurement of fluid status, the fluid status information indicating a current fluid status of the patient, and determine a treatment recommendation for the patient based on the fluid status information. Other embodiments are described.Type: ApplicationFiled: October 28, 2021Publication date: November 30, 2023Inventors: Matthias Kuss, Peter Kotanko
-
Publication number: 20230352183Abstract: Described herein are computer systems and methods for generating, in silico, one or more virtual patients. The one or more virtual patients can be used, for example, to conduct a virtual clinical trial, such as to determine an efficacy of a therapy or medical device. The one or more virtual patients mathematically represent a physiological system in an actual patient for a health condition. Also, the one or more virtual patients can be used, for example, to determine an adverse effect from a therapy or any other deviation from a therapy, or compliance of a patient suffering from a health condition on a therapeutic protocol.Type: ApplicationFiled: April 1, 2022Publication date: November 2, 2023Applicant: Fresenius Medical Care Holdings, Inc.Inventors: Doris Fuertinger, Franz Kappel, Peter Kotanko, Stephan Thijssen
-
Patent number: 11759556Abstract: The present teachings generally include parabiotic dialysis systems and techniques. For example, the present disclosure includes parabiotic liver dialysis, e.g., for use in settings with limited resources. To this end, a parabiotic liver dialysis system may include a device having a semipermeable membrane with an average pore size that allows for the passage of albumin therethrough. In such a system, a first extracorporeal circuit may connect the device to the vascular system of a first animal (e.g., a liver patient), and a second extracorporeal circuit may connect the device to the vascular system of a second animal (e.g., a human with normal liver function), where the exchange of albumin therebetween is facilitated through the device. The present disclosure also includes various safety measures for parabiotic dialysis systems and techniques, such as biometric verification systems and techniques.Type: GrantFiled: June 21, 2021Date of Patent: September 19, 2023Assignees: Fresenius Medical Care Holdings, Inc., Fresenius Medical Care Deutschland GmbH, Fresenius Medical Care AG & Co. KGaAInventors: Stefan Weiss, Peter Kotanko, Roland Sander
-
Patent number: 11744930Abstract: A hemodialysis system includes: a hemodialysis machine configured to provide hemodialysis treatment to a patient, wherein the hemodialysis treatment includes circulating extracorporeal blood of the patient through an extracorporeal blood circuit; a first oxygen saturation sensor device configured to measure oxygen saturation corresponding to the extracorporeal blood of the patient in the extracorporeal blood circuit; a second oxygen saturation sensor device configured to measure oxygen saturation corresponding to blood flowing within the patient; and at least one controller configured to determine one or more oxygen saturation phase shift (OSPS) values or one or more transcutaneous travel time values corresponding to the patient based on oxygen saturation measurements from the first oxygen saturation sensor device and the second oxygen saturation sensor device.Type: GrantFiled: April 6, 2020Date of Patent: September 5, 2023Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Peter Kotanko, Stephan Thijssen, Priscila Preciado, Israel D. Campos, Xia Tao
-
Publication number: 20230238077Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.Type: ApplicationFiled: March 30, 2023Publication date: July 27, 2023Inventors: Xia Tao, Vaibhav Maheshwari, Peter Kotanko, Stephan Thijssen, Nadja Grobe
-
Publication number: 20230201438Abstract: Compounds, systems, kits, methods, and/or apparatuses may be operative to reduce amyloid beta (A?) peptide in a patient, including a central nervous system (CNS) of the patient and/or a periphery (non-CNS portion) of the patient. In some embodiments, a displacer fluid comprising a A? displacer may be introduced to the patient to bind to a blood protein, such as albumin, that binds A? (for instance, A? peptide or non-plaque A?) in the patient periphery. Binding of the displacer to the blood protein may facilitate more free A? peptide (for instance, A? monomers) in the periphery for clearance via natural processes, such as through the liver or kidneys, and/or artificial processes, such as dialysis. Increased removal of the free A? peptide in the periphery may ultimately lead to less A? peptide in the CNS, which may decrease A? plaque formation in Alzheimer's Disease (AD) patients. Other embodiments are described.Type: ApplicationFiled: December 19, 2022Publication date: June 29, 2023Inventors: Xia Tao, Peter Kotanko, Stephan Thijssen, Vaibhav Maheshwari
-
Publication number: 20230166017Abstract: Techniques for monitoring intraperitoneal volume (IPV) during a dwell period of a peritoneal dialysis patient include monitoring intraperitoneal pressure (IPP) during the dwell period using a pressure sensor, monitoring the density of the dialysate during the dwell period, and determining a change in IPV based at least on a change in IPP and a change in the density of the dialysate during the dwell period.Type: ApplicationFiled: November 22, 2022Publication date: June 1, 2023Inventors: Fansan Zhu, Peter Kotanko, Laura Rosales, Jun Yi
-
Patent number: 11640846Abstract: Systems, methods, and/or apparatuses may be operative to perform a dialysis process that includes a displacer infusion process. In one embodiment, a method for determining a displacer compound may include constructing a plurality of target protein quantitative structure-activity relationship (QSAR) models, one for each of the plurality of binding sites, analyzing a set of candidate compounds using the plurality of QSAR models to determine a set of at least one potential compound with an affinity for binding to each of the plurality of binding sites, and selecting at least one displacer compound from the set of at least one potential compound. Other embodiments are described.Type: GrantFiled: January 29, 2021Date of Patent: May 2, 2023Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Xia Tao, Vaibhav Maheshwari, Peter Kotanko, Stephan Thijssen, Nadja Grobe
-
Patent number: 11623032Abstract: Techniques and apparatus for de-priming processes are described. For example, in one embodiment, an apparatus may include at least one processor and a memory coupled to the at least one processor, the memory may include instructions that, when executed by the processor, may cause the at least one processor to determine a priming volume of a primer fluid infused into a priming system associated with the patient during a priming phase of the dialysis treatment, cause an ultrafiltration rate of an ultrafiltration pump of the dialysis machine in fluid communication with the patient to be changed from a treatment ultrafiltration rate to a de-priming ultrafiltration rate to remove the priming volume over a de-priming time period, and cause, after the de-priming time period, the ultrafiltration rate of the ultrafiltration pump to be changed back the treatment ultrafiltration rate. Other embodiments are described.Type: GrantFiled: October 2, 2020Date of Patent: April 11, 2023Assignee: Fresenius Medical Care Holdings, Inc.Inventors: Peter Kotanko, Stephan Thijssen
-
Publication number: 20230106535Abstract: The described technology may include processes to model parathyroid gland (PTG) functionality and/or calcimimetic administration to healthy subjects and/or patients with a health abnormality that affects PTG function. In one embodiments, a computer-implemented method of calcimimetic analysis of PTG functionality may include accessing a calcimimetic model configured to simulate a functionality of a PTG of at least one patient, the calcimimetic model comprising at least one of a pharmacokinetic model or a pharmacodynamic model, providing a calcimimetic administration of a calcimimetic to the at least one patient via the calcimimetic model according to an administration process, and determining calcimimetic information based on the calcimimetic administration via the calcimimetic model for the at least one patient, the calcimimetic information configured to indicate an efficacy of the calcimimetic administration. Other embodiments are described.Type: ApplicationFiled: October 1, 2021Publication date: April 6, 2023Inventors: Gudrun Schappacher-Tilp, Peter Kotanko
-
Patent number: 11607145Abstract: A dialysis access site monitoring system may generate a treatment recommendation for treating a condition of an access site based on a video of the access site. The dialysis access site monitoring system may include an apparatus having a processor and a memory coupled to the processor. The memory may include instructions that, when executed by the processor, may cause the processor to generate video information based on a video of a dialysis access site of a patient, determine change in the number of pixels (CNP) information of the video information, the CNP information associated with movement of a skin surface of the patient due to blood flow through the dialysis access site, determine frequency domain information of the CNP information, determine a maximum-to-median power (M2) value of the frequency domain information, and determine at least one access site characteristic based on the M2 value.Type: GrantFiled: November 8, 2019Date of Patent: March 21, 2023Assignee: FRESENIUS MEDICAL CARE HOLDINGS, INC.Inventors: Fansan Zhu, Peter Kotanko
-
Patent number: 11565028Abstract: Techniques and apparatuses for determining an estimated cardiac output for a patient during dialysis treatment are described. In one embodiment, for example, an apparatus may include a memory and logic coupled to the memory. The logic may be configured to determine an upper body oxygen consumption for a patient, determine, during a dialysis process: a hemoglobin concentration and a venous oxygen saturation measured via an optical blood monitor operably coupled to an extracorporeal circuit of a dialysis system performing the dialysis process; an arterial oxygen saturation measured via a pulse oximeter operably coupled to the extracorporeal circuit; an arterial-venous oxygen content difference based on the arterial oxygen saturation and the venous oxygen saturation; and an upper body blood flow (UBBF) as (upper body oxygen consumption)/(arterial-venous oxygen content difference), and determine a treatment recommendation based on the upper body blood flow. Other embodiments are described.Type: GrantFiled: July 27, 2020Date of Patent: January 31, 2023Assignee: FRESENIUS MEDICAL CARE HOLDINGS, INC.Inventors: Peter Kotanko, Stephan Thijssen, Israel Campos, Hanje Zhang